Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus XYLOCAINE 4 PRESERVATIVE FREE.
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine blocks voltage-gated sodium channels on neuronal membranes, inhibiting the propagation of action potentials and resulting in local anesthesia.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
0.25-0.5% solution, up to 2 mg/kg (max 150 mg) per dose via infiltration, peripheral nerve block, or epidural; may repeat every 3-6 hours as needed. For epidural: 0.5% solution, 15-20 mL for surgical anesthesia.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is 2.7 hours (range 1.5-5.5 hours). Prolonged up to 8-10 hours in neonates and 24-48 hours in severe hepatic impairment.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Renal excretion accounts for approximately 95% of the dose, with about 50% excreted unchanged. The remainder is primarily hepatic metabolism followed by renal elimination of metabolites. Biliary/fecal excretion is minimal (<5%).
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic